Cysteinyl leukotriene receptor 1 mediates LTD 4-induced activation of mouse microglial cells in vitro

Acta Pharmacologica Sinica

Volumn 35, Issue 1, 2014, Pages 33-40

  Yu, Shu Ying ^a,b   Zhang, Xia Yan ^a   Wang, Xiao Rong ^a   Xu, Dong Min ^a   Chen, Lu ^c   Zhang, Li Hui ^c   Fang, San Hua ^a   Lu, Yun Bi ^a   Zhang, Wei Ping ^a   Wei, Er Qing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Hangzhou Pediatric Hospital   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

brain ischemia; cysteinyl leukotriene receptor; HAMI 3379; IL 1 ; inflammation; leukotriene D4; microglia; montelukast; phagocytosis

Indexed keywords

CYSTEINYL LEUKOTRIENE 1 RECEPTOR; CYSTEINYL LEUKOTRIENE 2 RECEPTOR; INTERLEUKIN 1BETA; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; MONTELUKAST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOL; IN VITRO STUDY; MICROGLIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOTRIENE D4; MICE; MICROGLIA; RECEPTORS, LEUKOTRIENE;

EID: 84891800998     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.130     Document Type: Article

References (45)

1. Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010; 85: 336-49.
2. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007; 27: 469-527. (Pubitemid 46984658)
3. Back M, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011; 63: 539-84.
4. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003; 55: 195-227. (Pubitemid 36268403)
5. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173: 1503-10. (Pubitemid 38971578)
6. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010; 117: 949-60.
7. Zhou Y, Fang SH, Ye YL, Chu LS, Zhang WP, Wang ML, et al. Caffeic acid ameliorates early and delayed brain injuries after focal cerebral ischemia in rats. Acta Pharmacol Sin 2006; 27: 1103-10. (Pubitemid 44410989)
8. Zhou Y, Wei EQ, Fang SH, Chu LS, Wang ML, Zhang WP, et al. Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 2006; 79: 1645-56. (Pubitemid 44349150)
9. Zhao CZ, Zhao B, Zhang XY, Huang XQ, Shi WZ, Liu HL, et al. Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats. Neuroscience 2011; 189: 1-11.
10. Fang SH, Wei EQ, Zhou Y, Wang ML, Zhang WP, Yu GL, et al. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 2006; 140: 969-79. (Pubitemid 43767454)
11. Fang SH, Zhou Y, Chu LS, Zhang WP, Wang ML, Yu GL, et al. Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci Lett 2007; 412: 78-83. (Pubitemid 46038560)
12. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin 2002; 23: 871-7.
13. Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, et al. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res 2012; 1484: 57-67.
14. Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. Br J Pharmacol 2010; 160: 399-409.
15. Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose-and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 2005; 73: 31-40.
16. Huang XJ, Zhang WP, Li CT, Shi WZ, Fang SH, Lu YB, et al. Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia 2008; 56: 27-37.
17. Ballerini P, Di Iorio P, Ciccarelli R, Caciagli F, Poli A, Beraudi A, et al. P2Y1 and cysteinyl leukotriene receptors mediate purine and cysteinyl leukotriene co-release in primary cultures of rat microglia. Int J Immunopathol Pharmacol 2005; 18: 255-68. (Pubitemid 40825888)
18. Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, Leist M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 2009; 26: 83-94.
19. Wang Y, Wang B, Zhu MT, Li M, Wang HJ, Wang M, et al. Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol Lett 2011; 205: 26-37.
20. Park HY, Kim ND, Kim GY, Hwang HJ, Kim BW, Kim WJ, et al. Inhibitory effects of diallyl disulfide on the production of inflammatory mediators and cytokines in lipopolysaccharide-activated BV2 microglia. Toxicol Appl Pharmacol 2012; 262: 177-84.
21. Luo JY, Zhang Z, Yu SY, Zhao B, Zhao CZ, Wang XX, et al. Rotenone-induced changes of cysteinyl leukotriene receptor 1 expression in BV2 microglial cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40: 131-8.
22. Zhang LP, Zhao CZ, Shi WZ, Qi LL, Lu YB, Zhang YM, et al. Preparation and identification of polyclonal antibody against cysteinyl leukotriene receptor 2. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009; 38: 591-7.
23. Schrijvers DM, Martinet W, De Meyer GR, Andries L, Herman AG, Kockx MM. Flow cytometric evaluation of a model for phagocytosis of cells undergoing apoptosis. J Immunol Methods 2004; 287: 101-8. (Pubitemid 38510212)
24. Campos MR, Serezani CH, Peters-Golden M, Jancar S. Differential kinase requirement for enhancement of Fc gammaR-mediated phagocytosis in alveolar macrophages by leukotriene B4 vs D4. Mol Immunol 2009; 46: 1204-11.
25. Porreca E, Conti P, Feliciani C, Di Febbo C, Reale M, Mincione G, et al. Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells. Atherosclerosis 1995; 115: 181-9.
26. Ozkan E, Akyuz C, Sehirli AO, Topaloglu U, Ercan F, Sener G. Montelukast, a selective cysteinyl leukotriene receptor 1 antagonist, reduces cerulein-induced pancreatic injury in rats. Pancreas 2010; 39: 1041-6.
27. Hui Y, Yang G, Galczenski H, Figueroa DJ, Austin CP, Copeland NG, et al. The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 2001; 276: 47489-95.
28. Martin V, Sawyer N, Stocco R, Unett D, Lerner MR, Abramovitz M, et al. Molecular cloning and functional characterization of murine cysteinyl- leukotriene 1 (CysLT1) receptors. Biochem Pharmacol 2001; 62: 1193-200. (Pubitemid 33055623)
29. Parhamifar L, Sime W, Yudina Y, Vilhardt F, Morgelin M, Sjolander A. Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells. PLoS One 2010; 5: e14439.
30. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110: 3263-70. (Pubitemid 350106319)
31. Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther 2013; 346: 328-41.
32. Kaur C, Sivakumar V, Foulds WS, Luu CD, Ling EA. Hypoxia-induced activation of N-methyl-D-aspartate receptors causes retinal ganglion cell death in the neonatal retina. J Neuropathol Exp Neurol 2012; 71: 330-47.
33. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 2013; 256: 13-8.
34. Gemma C, Bickford PC. Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. Rev Neurosci 2007; 18: 137-48.
35. Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 2009; 9: 1177-88.
36. Fogal B, Hewett SJ. Interleukin-1beta: a bridge between inflammation and excitotoxicity? J Neurochem 2008; 106: 1-23.
37. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012; 32: 1677-98.
38. Bandeira-Melo C, Hall JC, Penrose JF, Weller PF. Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin Immunol 2002; 109: 975-9. (Pubitemid 34634308)
39. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-94. (Pubitemid 350014685)
40. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009; 132: 288-95.
41. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-45.
42. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol 2010; 119: 89-105.
43. Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-Coyne D, Morath S, et al. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J Neurochem 2005; 92: 1439-51. (Pubitemid 40389213)
44. Yu GL, Wei EQ, Wang ML, Zhang WP, Zhang SH, Weng JQ, et al. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res 2005; 1053: 116-25.
45. Zhao R, Shi WZ, Zhang YM, Fang SH, Wei EQ. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol 2011; 63: 550-7.